Ph-Negative Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults (AYA) Treated with Pediatric Argentine BFM-like Protocol: Real-Word Data on Prognostic Factors and Treatment

Background: ALL in adults is considered a heterogeneous disease with poor prognosis. However, adolescents and young adults (AYA) display intermediate characteristics as compared with children. Risk groups and response predictors are essential to guide the treatment. Aims: The aim of this report was...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2021-11, Vol.138 (Supplement 1), p.4471-4471
Hauptverfasser: Ferrari, Luciana C, Rivas, María M, Fernandez, Isolda I, Sackmann, Federico, Mela Osorio, María J, Navickas, Alicia B, Agamennoni, Lucía, Rey, Irene, Aguerre, Laura, Dick, Hernan, Carnelutto, Natalia, Gómez, Mariela, Castro, María B, Basquiera, Ana L, Moya, Eliana, Negri Aranguren, Florencia, Negri Aranguren, Pedro, Fishman, Laura, Costa, Lucila, Cazap, Nicolás, Fornillo, Florencia, Paganini, María I, Rapan, María L, Freue, Julian, Clavijo, Manuela, Ramírez, Roxana, Milone, Jorge, Pavlovsky, Miguel A, Belli, Carolina B, Moirano, María M, Argentine Society of Hematology, On behalf of Acute Leukemia Committee
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: ALL in adults is considered a heterogeneous disease with poor prognosis. However, adolescents and young adults (AYA) display intermediate characteristics as compared with children. Risk groups and response predictors are essential to guide the treatment. Aims: The aim of this report was to evaluate the experience of Ph-negative ALL in AYA patients (pts) treated with the pediatric Argentine type-BFM protocol, assessing predictors of response in terms of overall survival (OS) and event-free survival (EFS). Methods: We performed a retrospective multicenter analysis of AYA pts diagnosed between 2013 to 2021, from 16 Argentine institutions who were treated following the pediatric Argentine type-BFM protocol. Response to prednisone (PR) at day(d) 8 (
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2021-151448